Satsuma Pharmaceuticals Inc (STSA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:STSA • US80405P1075

1.1 USD
-0.01 (-0.9%)
At close: Jun 7, 2023
1.07 USD
-0.03 (-2.73%)
After Hours: 6/7/2023, 8:00:00 PM
Fundamental Rating

2

Overall STSA gets a fundamental rating of 2 out of 10. We evaluated STSA against 191 industry peers in the Pharmaceuticals industry. While STSA seems to be doing ok healthwise, there are quite some concerns on its profitability. STSA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • STSA had negative earnings in the past year.
  • STSA had a negative operating cash flow in the past year.
STSA Yearly Net Income VS EBIT VS OCF VS FCFSTSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

  • The profitability ratios for STSA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
STSA Yearly ROA, ROE, ROICSTSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 -2K -4K

1.3 Margins

  • STSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STSA Yearly Profit, Operating, Gross MarginsSTSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

  • STSA has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for STSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STSA Yearly Shares OutstandingSTSA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M
STSA Yearly Total Debt VS Total AssetsSTSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -6.49, we must say that STSA is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of STSA (-6.49) is worse than 67.28% of its industry peers.
  • STSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.49
ROIC/WACCN/A
WACCN/A
STSA Yearly LT Debt VS Equity VS FCFSTSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 7.44 indicates that STSA has no problem at all paying its short term obligations.
  • STSA's Current ratio of 7.44 is fine compared to the rest of the industry. STSA outperforms 71.89% of its industry peers.
  • A Quick Ratio of 7.44 indicates that STSA has no problem at all paying its short term obligations.
  • STSA's Quick ratio of 7.44 is fine compared to the rest of the industry. STSA outperforms 73.27% of its industry peers.
Industry RankSector Rank
Current Ratio 7.44
Quick Ratio 7.44
STSA Yearly Current Assets VS Current LiabilitesSTSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for STSA have decreased strongly by -12.92% in the last year.
EPS 1Y (TTM)-12.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, STSA will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.03% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.57%
EPS Next 2Y31.44%
EPS Next 3Y22.81%
EPS Next 5Y15.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
STSA Yearly Revenue VS EstimatesSTSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M
STSA Yearly EPS VS EstimatesSTSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for STSA. In the last year negative earnings were reported.
  • Also next year STSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STSA Price Earnings VS Forward Price EarningsSTSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STSA Per share dataSTSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • STSA's earnings are expected to grow with 22.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.44%
EPS Next 3Y22.81%

More info and screens

0

5. Dividend

5.1 Amount

  • STSA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Satsuma Pharmaceuticals Inc / STSA FAQ

What is the fundamental rating for STSA stock?

ChartMill assigns a fundamental rating of 2 / 10 to STSA.


Can you provide the valuation status for Satsuma Pharmaceuticals Inc?

ChartMill assigns a valuation rating of 2 / 10 to Satsuma Pharmaceuticals Inc (STSA). This can be considered as Overvalued.


What is the profitability of STSA stock?

Satsuma Pharmaceuticals Inc (STSA) has a profitability rating of 1 / 10.


What is the financial health of Satsuma Pharmaceuticals Inc (STSA) stock?

The financial health rating of Satsuma Pharmaceuticals Inc (STSA) is 4 / 10.